Legacy Wealth Asset Management LLC Has $258,000 Position in Halozyme Therapeutics, Inc. $HALO

Legacy Wealth Asset Management LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 25.6% in the second quarter, HoldingsChannel.com reports. The fund owned 4,955 shares of the biopharmaceutical company’s stock after acquiring an additional 1,010 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Halozyme Therapeutics were worth $258,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of HALO. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 1,865 shares during the period. QRG Capital Management Inc. acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $281,000. Oppenheimer & Co. Inc. acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $625,000. Retirement Guys Formula LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $214,000. Finally, Spire Wealth Management grew its stake in shares of Halozyme Therapeutics by 9,919.0% in the 1st quarter. Spire Wealth Management now owns 14,227 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 14,085 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at $1,840,207.26. The trade was a 45.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,227 shares of company stock valued at $7,779,595. 2.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on HALO. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price for the company in a research note on Tuesday, October 14th. JMP Securities raised their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $72.89.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $66.88 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of 15.30, a PEG ratio of 0.36 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm’s 50-day simple moving average is $71.69 and its 200 day simple moving average is $62.17.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter last year, the firm earned $0.91 EPS. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.